Pentraxin-3 – a promising biological marker in heart failure: literature review

Cover Page

Cite item

Full Text

Abstract

According to many studies, inflammation plays a very significant role in the pathogenesis of heart failure. Many studies have demonstrated an increase in circulating levels of inflammatory markers and cytokines such as C-reactive protein, tumor necrosis factor-a (TNF-a), and interleukins. C-reactive protein is produced in the liver in response to stimulation by various cytokines, mainly interleukin-6, and is a member of the pentraxin superfamily. Pentraxin-3, which is a long pentraxin, has a C-terminal domain of pentraxin similar to the classic short pentraxins, but differs from them in the presence of an unrelated long N-terminal domain. Various cell types can produce pentraxin-3 when exposed to primary inflammatory signals such as interleukin-1, tumor necrosis (TNF-a), oxidized low density lipoprotein, and microbial fragments (eg, lipopolysaccharide, lipoarabinomannans). Data in experimental animal models have demonstrated that pentraxin-3 can play cardioprotective and atheroprotective roles through its influence on the inflammatory process. Pentraxin-3 has been studied in several clinical protocols as a potential biomarker for cardiovascular disease.

About the authors

Amina M. Alieva

Pirogov Russian National Research Medical University

Author for correspondence.
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0001-5416-8579
SPIN-code: 2749-6427

Cand. Sci. (Med.), Pirogov Russian National Research Medical University

Russian Federation, Moscow

Natalia V. Teplova

Pirogov Russian National Research Medical University

Email: amisha_alieva@mail.ru
ORCID iD: 0000-0002-7181-4680

D. Sci. (Med.), Prof., Pirogov Russian National Research Medical University

Russian Federation, Moscow

Maxim A. Batov

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: m.batov112@gmail.com
ORCID iD: 0000-0002-3780-4358
SPIN-code: 5850-7711

Medical Resident, Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Russian Federation, Moscow

Kira V. Voronkova

Pirogov Russian National Research Medical University; Central Clinical Hospital RAS

Email: kiravoronkova@yandex.ru
SPIN-code: 1636-7627

D. Sci. (Med.), Pirogov Russian National Research Medical University, Central Clinical Hospital RAS

Russian Federation, Moscow; Moscow

Ramiz K. Valiev

Loginov Moscow Clinical Research Center

Email: Radiosurgery@bk.ru
ORCID iD: 0000-0003-1613-3716
SPIN-code: 2855-2867

Cand. Sci. (Med.), Loginov Moscow Clinical Research Center

Russian Federation, Moscow

Lidia M. Shnakhova

Sechenov First Moscow State Medical University (Sechenov University)

Email: shnakhova_l_m@staff.sechenov.ru
ORCID iD: 0000-0003-3000-0987

therapist, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Tatiana V. Pinchuk

Pirogov Russian National Research Medical University

Email: doktor2000@inbox.ru
ORCID iD: 0000-0002-7877-4407

Cand. Sci. (Med.), Pirogov Russian National Research Medical University

Russian Federation, Moscow

Alik M. Rakhaev

Main Bureau of Medical and Social Expertise in the Kabardino-Balkar Republic

Email: alikrahaev@yandex.ru
ORCID iD: 0000-0001-9601-1174

D. Sci. (Med.), Main Bureau of Medical and Social Expertise in the Kabardino-Balkar Republic

Russian Federation, Nalchik

Marina R. Kalova

Pirogov Russian National Research Medical University

Email: marina717717@mail.ru
ORCID iD: 0000-0002-8949-4523

Graduate Student, Pirogov Russian National Research Medical University

Russian Federation, Moscow

Igor G. Nikitin

Pirogov Russian National Research Medical University

Email: igor.nikitin.64@mail.ru
ORCID iD: 0000-0003-1699-0881

D. Sci. (Med.), Prof., Pirogov Russian National Research Medical University

Russian Federation, Moscow

References

  1. Алиева А.М., Резник Е.В., Гасанова Э.Т., и др. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018;8(5):333-45 [Alieva AM, Reznik EV, Gasanova ET, et al. Clinical value of blood biomarkers in patients with chronic heart failure. The Russian Archive of Internal Medicine. 2018;8(5):333-45 (in Russian)]. DOI:10.20514 / 2226-6704-2018-8-5-333-345
  2. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;8(136):7-13 [Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russ J Cardiol. 2016;8(136):7-13 (in Russian)]. doi: 10.15829/1560-4071-2016-8-7-13
  3. Braunwald E. Heart Failure. JACC Heart Fail. 2013;1(1):1-20. doi: 10.1016/j.jchf.2012.10.002
  4. Гаспарян А.Ж., Шлевков Н.Б., Скворцов А.А. Возможности современных биомаркеров для оценки риска развития желудочковых тахиаритмий и внезапной сердечной смерти у больных хронической сердечной недостаточностью. Кардиология. 2020;60(4):101-8 [Gasparyan AZh, Shlevkov NB, Skvortsov AA. Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure. Kardiologiia. 2020;60(4):101-8 (in Russian)]. doi: 10.18087/cardio.2020.4.n487
  5. Алиева А.М., Байкова И.Е., Кисляков В.А., и др. Галектин-3: диагностическая и прогностическая ценность определения у пациентов с хронической сердечной недостаточностью. Терапевтический архив. 2019;91(9):145-9 [Aliyeva AM, Baykova IE, Kislyakov VA, et al. Galactin-3: diagnostic and prognostic value in patients with chronic heart failure. Terapevticheskii arkhiv (Ter. Arkh.). 2019;91(9):145-9 (in Russian)]. doi: 10.26442/00403660.2019.09.000226
  6. Алиева А.М., Пинчук Т.В., Алмазова И.И., и др. Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью. Consilium Medicum. 2021;23(6):522-6 [Alieva AM, Pinchuk TV, Almazova II, et al. Сlinical value of blood biomarker ST2 in patients with chronic heart failure. Consilium Medicum. 2021;23(6):522-6 (in Russian)]. doi: 10.26442/20751753.2021.6.200606
  7. Алиева А.М., Алмазова И.И., Пинчук Т.В., и др. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020;22(5):83-6 [Alieva AM, Almazova II, Pinchuk TV, et al. Fractalkin and cardiovascular disease. Consilium Medicum. 2020;22(5):83-6 (in Russian)]. doi: 10.26442/20751753.2020.5.200186
  8. Chow SL, Maisel AS, Anand I, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017;135(22):e1054-91. doi: 10.1161/CIR.0000000000000490
  9. Авербах М.М. (мл.), Губкина М.Ф., Панова Л.В. Содержание пентраксина 3 и С-реактивного протеина в сыворотке крови у больных туберкулезом органов дыхания детей и подростков с деструктивными процессами и малыми формами туберкулеза. Туберкулез и болезни легких. 2016;94(9):44-8 [Averbakh MM (J.), Gubkina MF, Panova LV. Content of pentraxin-3 and C-reactive protein in blood serum of children and adolescents suffering from respiratory tuberculosis with destruction and minor forms of the disease. Tuberculosis and Lung Diseases. 2016;94(9):44-8 (in Russian)]. doi: 10.21292/2075-1230-2016-94-9-44-48
  10. Ristagno G, Fumagalli F, Bottazzi B, et al. Pentraxin 3 in Cardiovascular Disease. Front Immunol. 2019;10:823. doi: 10.3389/fimmu.2019.00823
  11. Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007;204(4):793-804. doi: 10.1084/jem.20061301
  12. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120(8):699-708. doi: 10.1161/CIRCULATIONAHA.108.806547
  13. Yamasaki K, Kurimura M, Kasai T, et al. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009;47(4):471-7. doi: 10.1515/CCLM.2009.110
  14. Nymo SH, Aukrust P, Kjekshus J, et al. Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. JACC Heart Fail. 2017;5(4):256-64. doi: 10.1016/j.jchf.2017.01.008
  15. Ishino M, Takeishi Y, Niizeki T, et al. Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3. Circ J. 2008;72(11):1800-5. doi: 10.1253/circj.cj-08-0157
  16. Latini R, Gullestad L, Masson S, et al. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail. 2012;14(9):992-9. doi: 10.1093/eurjhf/hfs092
  17. Liu H, Guo X, Yao K, et al. Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure. Biomed Res Int. 2015:817615. doi: 10.1155/2015/817615
  18. Matsubara J, Sugiyama S, Nozaki T, et al. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. J Am Heart Assoc. 2014;3(4):e000928. doi: 10.1161/JAHA.114.000928
  19. Cabiati M, Salvadori C, Verde A, Del Ry S. Pentraxin 3, a novel inflammatory marker in heart failure patients: its expression in whole blood as a function of clinical severity. Frontiers Drug Chemistry Clinical Res. 2018;1(3):1-5. doi: 10.15761/FDCCR.1000114
  20. Suzuki S, Takeishi Y. Molecular mechanisms and clinical features of heart failure. Fukushima J Med Sci. 2018;64(3):116-24. doi: 10.5387/fms.2018-17
  21. Chen W, Zhuang Y-S, Yang C-X, et al. The Protective Role of the Long Pentraxin PTX3 in Spontaneously Hypertensive Rats with Heart Failure. Cardiovasc Toxicol. 2021;21(10):808-19. doi: 10.1007/s12012-021-09671-0
  22. Базаева Е.В., Мясников Р.П., Метельская В.А., Бойцов С.А. Диагностическая значимость биохимических маркеров при хронической сердечной недостаточности со сниженной, пограничной и сохраненной фракцией выброса левого желудочка. Кардиология. 2017;57(3):39-45 [Bazaeva EV, Myasnikov RP, Metelskaya VA, Boytsov SA. Diagnostic value of biochemical markers in patients with chronic heart failure with reduced, borderline and preserved left ventricular ejection fraction. Kardiologiia. 2017;57(3):39-45 (in Russian)]. doi: 10.18565/cardio.2017.3.39-45
  23. Шепель Р.Н., Драпкина О.М., Булгакова Е.С., и др. Анализ уровня пентраксина-3 у пациентов с хронической сердечной недостаточностью ишемического генеза II–IV функциональных классов и метаболическим синдромом. Профилактическая медицина. 2020;23(5):124-31 [Shepel RN, Drapkina OM, Bulgakova ES, et al. Pentraxin-3 level analysis in patients with functional class II–IV ischemic chronic heart failure and metabolic syndrome. The Russian Journal of Preventive Medicine. 2020;23(5):124-31 (in Russian)]. doi: 10.17116/profmed202023051124
  24. Abernethy A, Raza S, Sun J-L, et al. Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2018;7(8):e007385. doi: 10.1161/JAHA.117.007385
  25. Yamamoto M, Seo Y, Ishizua T, et al. Comparison of Soluble ST2, Pentraxin-3, Galectin-3, and High-Sensitivity Troponin T of Cardiovascular Outcomes in Patients With Acute Decompensated Heart Failure. J Card Fail. 2021;27(11):1240-50. doi: 10.1016/j.cardfail.2021.05.025
  26. Zhang F-H, Zhao X-L, Feng S, An J-D. Change of serum levels of pentraxin-3 and syndecan-4 in children with chronic heart failure. CJCP. 2021;23(5):513-8. doi: 10.7499/j.issn.1008-8830.2101108
  27. Шепель Р.Н., Драпкина О.М. Ангиогенез у пациентов с хронической сердечной недостаточностью: фокус на эндотелиальный фактор роста сосудов, пентраксин-3 и трансформирующий фактор роста бета. Рациональная фармакотерапия в кардиологии. 2020;16(3):439-48 [Shepel RM, Drapkina OM. Angiogenesis in Patients with Chronic Heart Failure: Focus on Endothelial Vascular Growth Factor, Pentraxin-3 and Transforming Growth Factor Beta. Rational Pharmacotherapy in Cardiology. 2020;16(3):439-48 (in Russian)]. doi: 10.20996/1819-6446- 2020-05-02
  28. Гареева Д.Ф., Хамитова А.Ф., Лакман И.А., и др. Прогностическая значимость комбинации новых биомаркеров в долгосрочной стратификации неблагоприятных исходов у пациентов с инфарктом миокарда с подъемом сегмента ST. Российский кардиологический журнал. 2020;25(12):3948 [Gareeva DF, Khamitova AF, Lakman IA, et al. Prognostic significance of a combination of novel biomarkers in the long-term stratification of adverse outcomes in patients with ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(12):3948 (in Russian)]. doi: 10.15829/1560-4071-2020-3948
  29. Анкудинов А.С., Калягин А.Н. Анализ взаимосвязи иммунологических факторов и воспалительных маркеров с течением хронической сердечной недостаточности на фоне ревматоидного артрита. Кардиология. 2018;58(S10):4-8 [Ankudinov AS, Kalyagin AN. Analysis of the interrelation between immune factors and inflammatory markers, and the course of chronic heart failiure in patients with rheumathoid arthritis. Kardiologiia. 2018;58(S10):4-8 (in Russian)]. doi: 10.18087/cardio.2495
  30. Анкудинов А.С., Калягин А.Н. Иммунологическая оценка процесса фиброзирования миокарда у больных с хронической сердечной недостаточностью, ассоциированной с ревматоидным артритом. Известия высших учебных заведений. Поволжский регион. Медицинские науки. 2021;1(57):16-24 [Ankudinov AS, Kalyagin AN. Immunological assessment of myocardial fibrosis in patients with chronic heart failure associated with rheumatoid arthritis. University proceedings. Volga region. Medical sciences. 2021;1(57):16-24 (in Russian)]. doi: 10.21685/2072-3032-2021-1-2

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1

Download (480KB)
Indexing metadata
3. Fig. 2

Download (210KB)
Indexing metadata
4. Fig. 3

Download (104KB)
Indexing metadata
5. Fig. 4

Download (191KB)
Indexing metadata
6. Fig. 5

Download (108KB)
Indexing metadata
7. Fig. 6

Download (242KB)
Indexing metadata

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies